
Opinion|Videos|December 22, 2025
The Role of Treatment Center Coordinators for CAR T-Cell Therapy Administration in Myeloma
Maximilian Merz, MD, and Carrie Bellerive, BS, RN, BMTCN, explain the role of treatment center coordinators in CAR T-cell therapy administration in multiple myeloma.
Advertisement
Episodes in this series

Maximilian Merz, MD, and Carrie Bellerive, BS, RN, BMTCN, explain the critical role of treatment center coordinators in the delivery of CAR T-cell therapy for patients with multiple myeloma. They outline responsibilities spanning patient education, scheduling, coordination of leukapheresis, and post-infusion monitoring. Merz and Bellerive highlight how effective coordination helps optimize safety, efficiency, and patient experience throughout the CAR T-cell process.
Advertisement
Related to this article

Data from EXCALIBER-RRMM supported FDA accelerated approval of iberdomide plus daratumumab/dexamethasone in R/R multiple myeloma.

The FDA approved iberdomide-based therapy for relapsed myeloma, rejected a neuroendocrine tumor therapy, and more.

Pankit Vachhani, MD, discusses the importance of hematocrit control in the management of polycythemia vera.

Pembrolizumab plus denosumab produced a 31% ORR and 53% 6-month PFS rate in VEGFR-TKI-pretreated advanced clear cell renal cell carcinoma.

A new study suggests genomic newborn screening could identify children at risk for early cancers and enable earlier diagnosis and less toxic treatment.

The CLDN18.2/CD47 bispecific antibody spevatamig has received FDA fast track designation for advanced and metastatic biliary tract carcinoma.

Did you catch all of this week's top oncology news? Test your knowledge with OncLive's Weekly News Quiz.
Advertisement
Advertisement
Trending on OncLive
1
FDA Approves Iberdomide Plus Daratumumab/Dexamethasone for R/R Myeloma
2
The OncFive: Top Oncology Articles for the Week of 8/9
3
FDA Grants Fast Track Designation to Spevatamig in Advanced and Metastatic Biliary Tract Carcinoma
4
Novel Approaches for Hematocrit Control Are Driving Research in Polycythemia Vera
5

